Vanda Pharmaceuticals Inc
VNDA6.840USD
-0.190-2.70%
Close 12/23, 16:00（ET）Quotes delayed by 15 min
404.21MMarket Cap
LossP/E TTM
More Details of Vanda Pharmaceuticals Inc Company
Vanda Pharmaceuticals Inc. is a global biopharmaceutical company focused on the development and commercialization of therapies to address unmet medical needs and improve the lives of patients. The Company’s commercial portfolio consist of three products: Fanapt for the acute treatment of manic or mixed episodes associated with bipolar I disorder and the treatment of schizophrenia, HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) and for the treatment of nighttime sleep disturbances in Smith-Magenis syndrome (SMS) and PONVORY for the treatment of relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease and active secondary progressive disease. In addition, it has a number of drugs and/or additional indications for current products in development, including Bysanti, Tradipitant, Imsidolimab, VTR-297, VQW-765, and others. Bysanti is the active metabolite of Fanapt.
Vanda Pharmaceuticals Inc Info
Ticker SymbolVNDA
Company nameVanda Pharmaceuticals Inc
IPO dateApr 12, 2006
CEOPolymeropoulos (Mihael Hristos)
Number of employees368
Security typeOrdinary Share
Fiscal year-endApr 12
AddressSuite 300E
CityWASHINGTON
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code20037
Phone12027343400
Websitehttps://www.vandapharma.com/
Ticker SymbolVNDA
IPO dateApr 12, 2006
CEOPolymeropoulos (Mihael Hristos)
Company Executives of Vanda Pharmaceuticals Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Mihael Hristos Polymeropoulos, M.D.
Dr. Mihael Hristos Polymeropoulos, M.D.
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
2.34M
+0.43%
Mr. Gunther Birznieks
Mr. Gunther Birznieks
Senior Vice President - Business Development
Senior Vice President - Business Development
411.63K
+73.26%
Mr. Kevin Patrick Moran
Mr. Kevin Patrick Moran
Chief Financial Officer, Senior Vice President, Treasurer
Chief Financial Officer, Senior Vice President, Treasurer
329.46K
+118.08%
Mr. Richard W. Dugan
Mr. Richard W. Dugan
Lead Independent Director
Lead Independent Director
177.45K
+50.09%
Dr. Tage Honore, Ph.D.
Dr. Tage Honore, Ph.D.
Independent Director
Independent Director
123.47K
+92.19%
Ms. Anne Sempowski Ward
Ms. Anne Sempowski Ward
Independent Director
Independent Director
119.07K
+98.97%
Dr. Stephen Ray Mitchell, M.D.
Dr. Stephen Ray Mitchell, M.D.
Independent Director
Independent Director
97.08K
+116.43%
Mr. Timothy I. Williams
Mr. Timothy I. Williams
Senior Vice President, General Counsel, Secretary
Senior Vice President, General Counsel, Secretary
--
--
Ms. Phaedra S. Chrousos
Ms. Phaedra S. Chrousos
Independent Director
Independent Director
--
--
Mr. Joakim (Kim) Wijkstrom
Mr. Joakim (Kim) Wijkstrom
Senior Vice President, Chief Marketing Officer
Senior Vice President, Chief Marketing Officer
--
--
Name
Name/Position
Position
Shareholding
Change
Dr. Mihael Hristos Polymeropoulos, M.D.
Dr. Mihael Hristos Polymeropoulos, M.D.
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
2.34M
+0.43%
Mr. Gunther Birznieks
Mr. Gunther Birznieks
Senior Vice President - Business Development
Senior Vice President - Business Development
411.63K
+73.26%
Mr. Kevin Patrick Moran
Mr. Kevin Patrick Moran
Chief Financial Officer, Senior Vice President, Treasurer
Chief Financial Officer, Senior Vice President, Treasurer
329.46K
+118.08%
Mr. Richard W. Dugan
Mr. Richard W. Dugan
Lead Independent Director
Lead Independent Director
177.45K
+50.09%
Dr. Tage Honore, Ph.D.
Dr. Tage Honore, Ph.D.
Independent Director
Independent Director
123.47K
+92.19%
Ms. Anne Sempowski Ward
Ms. Anne Sempowski Ward
Independent Director
Independent Director
119.07K
+98.97%
Revenue Breakdown
Currency: USDUpdated: Mon, Oct 6
Currency: USDUpdated: Mon, Oct 6
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
FY2019
By BusinessUSD
Name
Revenue
Proportion
Fanapt
29.29M
55.70%
Hetlioz
16.19M
30.79%
PONVORY
7.10M
13.51%
Relevant data have not been disclosed by the company yet.
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
Fanapt
29.29M
55.70%
Hetlioz
16.19M
30.79%
PONVORY
7.10M
13.51%
Shareholding Stats
Updated: Sun, Nov 16
Updated: Sun, Nov 16
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
BlackRock Institutional Trust Company, N.A.
9.77%
The Vanguard Group, Inc.
6.02%
Renaissance Technologies LLC
5.88%
Millennium Management LLC
5.50%
Dimensional Fund Advisors, L.P.
4.34%
Other
68.49%
Shareholders
Shareholders
Proportion
BlackRock Institutional Trust Company, N.A.
9.77%
The Vanguard Group, Inc.
6.02%
Renaissance Technologies LLC
5.88%
Millennium Management LLC
5.50%
Dimensional Fund Advisors, L.P.
4.34%
Other
68.49%
Shareholder Types
Shareholders
Proportion
Investment Advisor
28.53%
Investment Advisor/Hedge Fund
27.12%
Hedge Fund
20.23%
Individual Investor
7.19%
Research Firm
1.71%
Pension Fund
0.27%
Bank and Trust
0.20%
Sovereign Wealth Fund
0.19%
Family Office
0.09%
Other
14.45%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
373
46.45M
78.60%
-9.99M
2025Q2
417
50.75M
85.90%
-11.31M
2025Q1
426
48.51M
82.37%
-12.27M
2024Q4
444
46.48M
79.71%
-15.23M
2024Q3
446
47.42M
81.36%
-14.93M
2024Q2
445
46.99M
80.73%
-18.42M
2024Q1
434
53.50M
92.97%
-11.41M
2023Q4
445
55.38M
96.27%
-9.21M
2023Q3
446
56.79M
98.75%
-12.15M
2023Q2
434
60.42M
105.19%
-10.16M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
BlackRock Institutional Trust Company, N.A.
5.99M
10.13%
-31.47K
-0.52%
Jun 30, 2025
The Vanguard Group, Inc.
3.54M
5.99%
+46.84K
+1.34%
Jun 30, 2025
Renaissance Technologies LLC
3.45M
5.83%
-118.97K
-3.34%
Jun 30, 2025
Millennium Management LLC
3.12M
5.28%
+980.75K
+45.84%
Jun 30, 2025
Dimensional Fund Advisors, L.P.
2.59M
4.38%
+46.08K
+1.81%
Jun 30, 2025
Tang Capital Management, LLC
2.35M
3.98%
--
--
Jun 30, 2025
Polymeropoulos (Mihael Hristos)
2.34M
3.95%
+10.00K
+0.43%
Aug 07, 2025
BlackRock Financial Management, Inc.
2.43M
4.12%
+286.64K
+13.35%
Jun 30, 2025
Acadian Asset Management LLC
1.73M
2.93%
-155.16K
-8.22%
Jun 30, 2025
Two Sigma Investments, LP
1.34M
2.26%
+925.23K
+225.21%
Jun 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
iShares Neuroscience and Healthcare ETF
0.49%
Invesco NASDAQ Future Gen 200 ETF
0.49%
SPDR SSGA US Small Cap Low Volatility Index ETF
0.12%
ALPS Medical Breakthroughs ETF
0.1%
Federated Hermes MDT Small Cap Core ETF
0.09%
iShares Micro-Cap ETF
0.05%
ProShares Ultra Nasdaq Biotechnology
0.04%
Franklin US Small Cap Multifactor Index ETF
0.04%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
0.04%
JPMorgan Diversified Return U.S. Small Cap Equity ETF
0.03%
View more
iShares Neuroscience and Healthcare ETF
Proportion0.49%
Invesco NASDAQ Future Gen 200 ETF
Proportion0.49%
SPDR SSGA US Small Cap Low Volatility Index ETF
Proportion0.12%
ALPS Medical Breakthroughs ETF
Proportion0.1%
Federated Hermes MDT Small Cap Core ETF
Proportion0.09%
iShares Micro-Cap ETF
Proportion0.05%
ProShares Ultra Nasdaq Biotechnology
Proportion0.04%
Franklin US Small Cap Multifactor Index ETF
Proportion0.04%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
Proportion0.04%
JPMorgan Diversified Return U.S. Small Cap Equity ETF
Proportion0.03%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Vanda Pharmaceuticals Inc?
The top five shareholders of Vanda Pharmaceuticals Inc are:
BlackRock Institutional Trust Company, N.A. holds 5.99M shares, accounting for 10.13% of the total shares.
The Vanguard Group, Inc. holds 3.54M shares, accounting for 5.99% of the total shares.
Renaissance Technologies LLC holds 3.45M shares, accounting for 5.83% of the total shares.
Millennium Management LLC holds 3.12M shares, accounting for 5.28% of the total shares.
Dimensional Fund Advisors, L.P. holds 2.59M shares, accounting for 4.38% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 5.99M shares, accounting for 10.13% of the total shares.
The Vanguard Group, Inc. holds 3.54M shares, accounting for 5.99% of the total shares.
Renaissance Technologies LLC holds 3.45M shares, accounting for 5.83% of the total shares.
Millennium Management LLC holds 3.12M shares, accounting for 5.28% of the total shares.
Dimensional Fund Advisors, L.P. holds 2.59M shares, accounting for 4.38% of the total shares.
What are the top three shareholder types of Vanda Pharmaceuticals Inc?
The top three shareholder types of Vanda Pharmaceuticals Inc are:
BlackRock Institutional Trust Company, N.A.
The Vanguard Group, Inc.
Renaissance Technologies LLC
BlackRock Institutional Trust Company, N.A.
The Vanguard Group, Inc.
Renaissance Technologies LLC
How many institutions hold shares of Vanda Pharmaceuticals Inc (VNDA)?
As of 2025Q3, 373 institutions hold shares of Vanda Pharmaceuticals Inc, with a combined market value of approximately 46.45M, accounting for 78.60% of the total shares. Compared to 2025Q2, institutional shareholding has increased by -7.30%.
What is the biggest source of revenue for Vanda Pharmaceuticals Inc?
In FY2025Q2, the Fanapt business generated the highest revenue for Vanda Pharmaceuticals Inc, amounting to 29.29M and accounting for 55.70% of total revenue.
